de Western Therapeutics Institute is a Japanese biopharmaceutical venture company focused on the research and development of protein kinase inhibitors, primarily Rho kinase inhibitors, with the mission of delivering innovative drugs from Japan to the world. The company develops drug candidates and generates revenue through licensing agreements with pharmaceutical companies, including upfront payments, milestone payments, and royalties. Its pipeline spans ophthalmology and pain therapeutics, with multiple products already commercialized globally, including Glaalpha (ripasudil/brimonidine combination eye drops for glaucoma in Japan/Asia) and ILM-Blue/TissueBlue (ophthalmic surgical aids in the US and Europe).